

File Copy
Attached to PAPER No. 17

PTO/SB/08A(10-01)
Approved for use through 10/31/2002. OMB 651-0031
US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Complete if Known

Application Number 09/458779

Filing Date December 10, 1999

First Named Inventor Latterich, Martin

Group Art Unit 1636

Examiner Name Davis, Katherine LAMBERTSON, DAVID

Attorney Docket No: 01211.001US1

Sheet 1 of 2

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
--------------------	---------------------	------------------	---	-------	----------	----------------------------

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²
---------------------	---------------------	------------------	---	-------	----------	----------------

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DL		"AFG1 Protein - Yeast (<i>Saccharomyces Cerevisiae</i>)", NCBI Protein S30825,	
DL		"agCP10084 [<i>Anopheles Gambiae</i> Str. PEST]", EAA07345,	
DL		"Alpha-soluble NSF Attachment Protein [<i>Arabidopsis Thaliana</i>]", NCBI Protein NP 191178,	
DL		"Alpha-soluble NSF Attachment Protein-like [<i>Arabidopsis thaliana</i>]", NCBI Protein - NP 191204,	
DL		"ATPase", NCBI Protein AAA34414,	
DL		"BLASTP 2.2.3 [April 24, 2002]",	
DL		"BLASTP 2.2.4 [August 26, 2002]",	
DL		"BRCA2 and CDKN1A-Interacting Protein Isoform BCCIPalpha; BRCA2 and CDKN1A-interacting Protein; cdk Inhibitor p21 binding protein; BCCIPbeta; TOK-1alpha; TOK-1beta [<i>Homo Sapiens</i>]", NCBI Protein - NP 057651,	
DL		"Hypothetical ORF; Bcp1p [<i>Saccharomyces Cerevisiae</i>]", NCBI Protein - NP 010648,	
DL		"Hypothetical Protein [<i>Schizosaccharomyces Pombe</i>]", NCBI Protein - NP 587696,	
DL		"Hypothetical Protein [<i>Schizosaccharomyces Pombe</i>]", NCBI Protein - CAA21060,	
DL		"Nsf, N-ethylmaleimide Sensitive Factor [<i>Rattus Norvegicus</i>]", NCBI Protein - NP 068516,	
DL		"SEC18 Protein - Yeast (<i>Saccharomyces Cerevisiae</i>)", NCBI Protein S45477,	
DL		"Unknown", NCBI Protein AAB60280,	
DL		"Vesicular-fusion protein NSF (N-ethylmaleimide-sensitive fusion protein) (NEM-sensitive fusion protein)", NCBI Protein P46459,	
DL		"Vesicular-fusion Protein NSF [<i>Caenorhabditis Elegans</i>]", NCBI Protein NP 492152,	
DL		"Vesicular-fusion Protein Nsf1 (N-ethylmaleimide-sensitive Fusion Protein 1) (NEM-sensitive Fusion Protein 1) (DNsf-1) (Comatose Protein)", NCBI Protein - P46461,	
DL		"Vesicular-fusion Protein Nsf2 (N-ethylmaleimide-sensitive Fusion Protein 2) (NEM-sensitive Fusion Protein 2) (DNsf-2)", NCBI Protein - P54351,	

EXAMINER

David Lambertson

DATE CONSIDERED

12/4/02

Substitute Disclosure Statement Form (PTO-1449)
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number 09/458779

Filing Date December 10, 1999

First Named Inventor Latterich, Martin

Group Art Unit 1636

Examiner Name ~~Davis, Katharine~~ LAMBERTSON, DAVID

Attorney Docket No: 01211.001US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>DJ</i>		"Vesicular-fusion Protein SEC18", NCBI Protein P34732,	
<i>DJ</i>		"Vesicular-fusion Protein Sec18.", NCBI Protein P18759,	

EXAMINER

David Lambertson

DATE CONSIDERED

12/4/02

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached